Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Glaukos Corporation or Boston Scientific Corporation because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Glaukos Corporation and Boston Scientific Corporation compare based on key financial metrics to determine which better meets your investment needs.

About Glaukos Corporation and Boston Scientific Corporation

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Latest Health Care Equipment & Supplies and Glaukos Corporation, Boston Scientific Corporation Stock News

As of August 19, 2026, Glaukos Corporation had a $11.2 billion market capitalization, compared to the Health Care Equipment & Supplies median of $425.3 million. Glaukos Corporation’s stock is up 64.8% in 2026, down 1.8% in the previous five trading days and up 111.74% in the past year.

Currently, Glaukos Corporation does not have a price-earnings ratio. Glaukos Corporation’s trailing 12-month revenue is $612.8 million with a -30.7% net profit margin. Year-over-year quarterly sales growth most recently was 49.6%. Analysts expect adjusted earnings to reach $-0.291 per share for the current fiscal year. Glaukos Corporation does not currently pay a dividend.

As of August 19, 2026, Boston Scientific Corporation had a $75.4 billion market cap, putting it in the 95th percentile of all stocks. Boston Scientific Corporation’s stock is down 48.1% in 2026, down 4.2% in the previous five trading days and down 49.53% in the past year.

Currently, Boston Scientific Corporation’s price-earnings ratio is 21.1. Boston Scientific Corporation’s trailing 12-month revenue is $21.0 billion with a 17.5% net profit margin. Year-over-year quarterly sales growth most recently was 7.5%. Analysts expect adjusted earnings to reach $3.304 per share for the current fiscal year. Boston Scientific Corporation does not currently pay a dividend.

How We Compare Glaukos Corporation and Boston Scientific Corporation Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Glaukos Corporation and Boston Scientific Corporation’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Glaukos Corporation and Boston Scientific Corporation Growth Grades

Company	Ticker	Growth
Glaukos Corporation	GKOS	D
Boston Scientific Corporation	BSX	A

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Glaukos Corporation has a Growth Score of 38, which is Weak. Boston Scientific Corporation has a Growth Score of 95, which is Very Strong.

The Growth Grade Winner: Boston Scientific Corporation

As you can clearly see from the Growth Grade breakdown above, Boston Scientific Corporation has a more attractive growth grade than Glaukos Corporation. For investors who focus solely on how a company is growing relative to other companies in the same industry, Boston Scientific Corporation could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Glaukos Corporation and Boston Scientific Corporation’s Momentum Grades

Company	Ticker	Momentum
Glaukos Corporation	GKOS	A
Boston Scientific Corporation	BSX	F

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Glaukos Corporation has a Momentum Score of 90, which is Very Strong. Boston Scientific Corporation has a Momentum Score of 13, which is Very Weak.

The Momentum Grade Winner: Glaukos Corporation

As you can clearly see from the Momentum Grade breakdown above, Glaukos Corporation is considered to have stronger momentum compared to Boston Scientific Corporation. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Glaukos Corporation could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Glaukos Corporation and Boston Scientific Corporation’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Glaukos Corporation	GKOS	B
Boston Scientific Corporation	BSX	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Glaukos Corporation has a Earnings Estimate Score of 73, which is Positive. Boston Scientific Corporation has a Earnings Estimate Score of 45, which is Neutral.

The Earnings Estimate Revisions Grade Winner: Glaukos Corporation

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Glaukos Corporation has a better Earnings Estimate Revisions Grade than Boston Scientific Corporation. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Glaukos Corporation could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Glaukos Corporation and Boston Scientific Corporation Grades

In addition to Momentum, Estimate Revisions and Growth, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Glaukos Corporation and Boston Scientific Corporation pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Glaukos Corporation or Boston Scientific Corporation Stock?

Overall, Glaukos Corporation stock has a Growth Score of 38, Momentum Score of 90 and Estimate Revisions Score of 73.

Boston Scientific Corporation stock has a Growth Score of 95, Momentum Score of 13 and Estimate Revisions Score of 45.

Comparing Glaukos Corporation and Boston Scientific Corporation’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.